Stock Scorer

Odyssey Therapeutics, Inc. (ODTX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. This filer's financial year end could not be read from its revenue history, so quarters are labelled by the calendar. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 700K 1.4M 2.1M Q1 '25: 1.9M Q2 '25: 959K Q1 '26: 0 Q2 '26: 0 Q1 '25 Q2 '25 Q1 '26 Q2 '26

Operating Income Quarterly

-60M -40M -20M 0 20M 40M 60M Q1 '25: -39.2M Q2 '25: -41.9M Q1 '26: -39.8M Q2 '26: -55.5M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Net Income Quarterly

-60M -40M -20M 0 20M 40M 60M Q1 '25: -38.4M Q2 '25: -41.2M Q1 '26: -38.3M Q2 '26: -52.8M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Operating Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q1 '25: -38.6M Q2 '25: -34.3M Q1 '26: -41M Q2 '26: -34.5M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Free Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q1 '25: -39.5M Q2 '25: -34.3M Q1 '26: -41.2M Q2 '26: -34.7M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q1 '25: 976.1K Q2 '25: 1.4M Q1 '26: 5.7M Q2 '26: 30.3M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

Not drawn for ODTX: Gross Profit, Cost of Revenue, EPS. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.